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interest is discussed; therapeutic goals and rehabilitation care are different than
in traumatic SCI and the benefit is difficult to be assessed.
Methods.– Retrospective study of patients admitted in PM&R hospitalization
for neoplastic paraplegia during the last 10 years at Nantes.
Data collected.– Demographics, clinical (cancer ASIA impairment scale (AIS),
survey), functional (functional independence measure (FIM), bladder manage-
ment) and therapeutics (surgery, radiotherapy).
Results.– Twenty paraplegia patients were reviewed. Prostate cancer was the
most frequent (35%). The patients were treated by surgery in 75% of case and
by radiotherapy in 70%. At the beginning of inpatient rehabilitation, AIS grade
patient status was: 6 AIS A, 2 AIS B, 7 C and 5 D. At the end of the stay, the
number of ambulatory patients changed from 3 to 6, 8 patients were urinary
independent and 8 showed an increase at their FIM scale. For 35% of patients,
a pressure ulcer was present at admission. It was 12.5% among patients coming
from neurosurgery, 33% of those coming from medicine units but 66% of those
coming from oncology units or follow-up care units. The average of length of
stay was 4 month. For the survivors, the median survival rate was 13 months.
Discussion.– In-hospital death rate is high, raising questions about PM&R hos-
pitalization aims. The functional advances remain low, often restricted by pain
and weakness. Bladder function evaluation is a PM&R specificity even if the
number of patients becoming urinary independent remains modest.
In light of these findings, the PM&R care management criteria for metastatic
paraplegia are progressively defined. They are based on well-defined goals,
defined by contract; have to be achieved during a one-month stay. For our cohort,
the duration of stay is too long, increased by ulcer pressure complications at
admission. This fact underlines the need to create a network of competence to
optimize patients’ care from acute units to PM&R unit discharge.
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Most patients treated for cancer have a sedentary life. In a Canadian study [1]
on more than 9000 patients having been treated for cancer, only 37.1% of the
breast cancer patients reached the physical activity level recommended by the
American Cancer Society.
Physical activity (PA) improves quality of life of patients with breast cancer and
decreases the recurrence rate. This is clearly shown for instance in the “nurses’
health study” [2], from a cohort of 121,700 women. It seems we have to offer
exercise sessions to patients during and after their breast cancer treatment. Many
studies showed the benefits of exercise programmes either in a structured group
or at home. These programmes last two to six months and improve quality of
life, fatigue and fitness. It remains difficult to build recommendations because
of the great variability of the exercise programmes available.
Adherence to the programme is usually good during the study time, but once
the experiment is over, physical activity practice decreases often quickly. The
best studies in the literature do not give data over six months. They show a fair
stability in physical capacity but a decrease of the daily physical activity amount.
Adherence to exercise prescription should be a priority subject of research to
achieve a sustainable improvement of the health status of these patients.
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Breast cancer related arm lymphoedema (BCRL) remains a relevant compli-
cation although it occurs less frequently thanks to the sentinel lymph node
biopsy.
When the BRRA is not treated, it can be responsible for severe limb swelling,
skin fibrosis and high infection risk. This morbidity negatively affects quality of
life.
The physical treatment is called complex decongestive physiotherapy. It is car-
ried out in two successive phases: the first intensive treatment aims to reduce
substantial lymphoedema volume and reduce the fibrous tissue. Manuel lymph
drainage (MLD), multilayer bandaging, specific exercise, and skin care are
needed. This treatment can be implemented either in hospital or at home.
The aim of the maintenance phase is to stabilize lymphoedeme volume, consis-
ting of a combination of custom-made sleeve-and-glove compression garments
worn during the day and self-bandaging technique if necessary. Frequency of
MLD treatment depends on the swelling and on patient involvement. Meticulous
skin hygiene is needed to avoid erysipela.
Patient education, regular activity and weight control are major component of
lymphoedema management to permit better maintenance or lead to an improve-
ment of the BCRL.
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Urinary, anorectal and sexual complications are often observed after pelvic can-
cer surgery. These symptoms may be secondary to a tumor compression or a
specific surgical trauma of autonomic and somatic pathways involved in the blad-
der, bowel and sexual control. Indeed, pelvic organs are very close and share
the same innervation, which plays an important role in the detrusor contrac-
tion, erectile function, pelvic floor contraction and global pelvi-perineal sensory
functions. Moreover, pelvic irradiation and/or chemotherapy following specific
surgery can also lead to neurogenic (myelopathy and plexopathy) lesions of cen-
ters and/or motor/sensory pathways, which control bladder and rectal functions.
Specific bladder and rectal lesions secondary to irradiation are very common
(chronic radiation cystitis, radiation rectitis). Sexual dysfunction from radiation
therapy includes erectile dysfunction and vaginal stenosis.
Urinary symptoms observed after pelvic surgery are principally characterized
by voiding dysfunction with urinary retention or post void residual in case
of neurogenic lesion. In some cases, overactive bladder symptoms (urge, fre-
quency) are due to a radiation lesion of the bladder mucosa. Cystoscopy and
urodynamic investigations are necessary to understand the different pathophy-
siological mechanisms of these symptoms. Treatment of urinary retention is
usually self-intermittent catherization and anticholinergic drugs can be used in
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case of overactive bladder. Phosphodiesterase type 5 inhibitors can be used in
male erectile dysfunction and vaginal dilators in case of vaginal stenosis. Perineal
pain can be observed. Neurological mechanism is the main mechanism and can
be confirmed by means of electrophysiological testing. This neuropathic pain
can be managed by various treatments (drugs, TENS. . .).
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The 4th measure of ministerial plan 2008–2012 relative to palliative care has
enabled the creation or the development of regional resources teams in charge
of pediatric palliative care.
In Rhone-Alpes, ESPPéRA (pediatric palliative team for supporting care,
resource and accompaniment) was created January 1st 2011 to communicate
about palliative approach and train health professionals in hospitals, medico-
social institutions or private practices.
Pediatric palliative cares were initially developed by pediatric oncologists for
children suffering from cancer; however, most children suffering from a patho-
logy “limiting or threatening life” present more broadly a disability at some
point in time in their care. At that point in time, a PMR team (physical medi-
cine and rehabilitation) or medico-social team (such as accompaniment services,
SESSAD, IME, CEM. . .) provides care for them.
These caregivers are mainly trained for re-education and rehabilitation approach,
which is similar to a palliative approach, as it relies on a care project which takes
into consideration the patient deficiencies and incapacities, and is integrated to
a life project without a cure outlook.
Yet, SSR or medico-social teams face difficulties when life is threatened at short
or mid term: difficulties in identifying a palliative situation, in adapting the care
project, in applying different techniques (such as palliative chemotherapy) or in
handling the end of life symptoms. More generally, these teams may not feel
comfortable or even legitimate at this moment of the child’s life.
I will first identify the different clinical situations that can lead a disabled child
to begin palliative care, and I will then develop the specificities and complemen-
tarities between cultures and practices of rehabilitation teams and SPP resource
teams. I will also consider how these teams could cross train each other.
doi:10.1016/j.rehab.2011.07.511
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Introduction.– Nous rapportons un cas de lymphome du manteau compliqué
d’une paraplégie après injection intrathécale de Méthotrexate.
Observation.– Une femme de 53 ans, caucasienne, se présente en novembre
2009 pour polyadénopathies cervicales. Une biopsie ganglionnaire est réalisée,
diagnostiquant un lymphome à cellules du manteau. Une chimiothérapie selon
le protocole LYMA (traitement d’entretien par Rituximab) est entreprise en
décembre 2009. Le 20 janvier 2010, la 2e cure est réalisée. Le lendemain, une
injection intrathécale comprenant Méthotrexate, Aracytine et Hydrocortisone est
effectuée. Huit jours plus tard, la patiente développe une paraplégie de niveau
moteur et sensitif Th9, flasque, avec rétention urinaire. L’électromyogramme
(EMG) a mis en évidence une atteinte pluriradiculaire. L’Imagerie par réso-
nance magnétique (IRM) élimine une compression médullaire, et retrouve un
œdème du cône terminal et de la mœlle dorsale basse sans prise de contraste
anormale. Un bilan étiologique exhaustif infectieux et auto-immun s’avère néga-
tif ; la ponction lombaire est normale. Le diagnostic de myélite secondaire à
l’injection intrathécale de Méthotrexate est retenu. Aucune amélioration n’est
constatée après bolus de corticoïdes. Treize mois après, l’IRM de contrôle montre
une atrophie de la mœlle avant le cône terminal. Depuis, la patiente a récu-
péré partiellement mais garde une paraparésie avec des troubles sensitifs encore
importants ; elle marche sur courtes distances avec 2 cannes.
Discussion.– La neurotoxicité après injection intrathécale de Méthotrexate est
une complication rare ; peu de cas ont été décrits dans la littérature [1,2]. Elle
peut prendre plusieurs formes : syndrome méningé, épilepsie, encéphalopathie,
paraplégie voire tétraplégie. Le mécanisme pathologique est encore inconnu ;
plusieurs facteurs ont été incriminés : diluant, conservateur, fuite de liquide
céphalo-rachidien, carence locale en folates. . . L’évolution est variable : récupé-
ration partielle ou complète. Contrairement à ce qui est décrit dans la littérature,
notre patiente a développé sa paraplégie dès la 1re injection.
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Introduction.– We report a case of mantle cell lymphoma complicated with
paraplegia after intrathecal injection of Methotrexate.
Case report.– A 53-year-old Caucasian woman consulted in November 2009
for cervical polyadenopathies. A node biopsy is performed, diagnosing mantle
cell lymphoma. Chemotherapy according to the protocol LYMA (Rituximab
maintenance regimen) was begun in December 2009. On January 20 2010,
the second cure was delivered. The next day, a lumbar puncture including
Methotrexate, Aracytine and Hydrocortisone was made. Eight days later,
the patient develops flask paraplegia of motor and sensory level Th9 with
urinary retention. The electromyography (EMG) brought to light a pluriradi-
cular impingement. The magnetic resonance imaging (MRI) eliminated cord
compression, and found an oedema of the terminal cone and the low dorsal
marrow without abnormal contrast uptake. The infectious and autoimmune
etiologic assessment was negative; the lumbar puncture was normal. The
diagnosis of secondary myelitis due to the intrathecal injection of Metho-
trexate was retained. No improvement was noticed after bolus of corticoids.
Thirteen months later, a follow-up MRI revealed medullary atrophy before
the terminal cone. Since, the patient recovered partially but paraparesis per-
sists with important sensory disorders; she can walk short distances with 2
crutches.
Discussion.– Neurotoxicity of intrathecal injections of Methotrexate is a rare
complication; not enough cases have been well documented in the literature
[1,2]. It can take several forms: meningeal irritation, epilepsy, encephalopathy,
paraplegia even quadriplegia. The pathological mechanism is still unknown;
several factors were incriminated: dilutant, preservatives, leakage of cerebrospi-
nal fluid, local folate deficiency. . . The evolution is variable: partial or complete
recovery. Contrary to what is described in the literature, our patient developed
the paraplegia after the first injection.
